Eye Tracking Technology in the Diagnosis of Neurological Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Demonstrating that diagnostics of the state of consciousness and cognitive functions of patients with consciousness disorders performed using C-Eye X (based on eye-tracking technology) allows a more objective assessment of state of patients who were wrongly diagnosed based on popular methods using in a clinical practice (like behavioural scales on paper forms).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Computer-based Cognitive Rehabilitation Program for Healthy Older Adults, Older People With Mild Cognitive Impairment and Mild Dementia

NCT03430401

Mild Cognitive Impairment Mild Dementia Healthy Older Adults

ACTIVE_NOT_RECRUITING NA

Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease

NCT05176704

Alzheimer's Disease

RECRUITING

Cognitive Ability Training in Seniors

NCT02587338

Mild Cognitive Impairment

COMPLETED NA

Cognitive Stimulation Study

NCT02067689

Healthy

COMPLETED NA

Evaluation of Cognitive State in Seniors Using Neurosteer EEG System

NCT05528445

Cognitive Decline

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this Study is to perform a clinical evaluation of the authors' original battery of diagnostic tests in the C-Eye X system (based on eye-tracking technology), addressed to patients who have suffered damage to the central nervous system (CNS) with communication barriers. Validation is being conducting for 2 original diagnostic tests: MCSD (Minimally Conscious State Detection): to differentiate patients' state of consciousness (for patients diagnosed as being in unresponsive wakefulness syndrome (UWS) or minimally consciousness state (MCS) and CFA (Cognitive Functions Assessment) to assess the level of preserved cognitive functions in patients (for patients diagnosed as being in at least minimally consciousness state minus (MCS-). The intention of the project's authors is to introduce a novel diagnostic solution that will help reduce misdiagnoses made for neurological patients with reduced consciousness, due to the inadequacy of current behavioural tools to work with patients after severe brain damage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postcomatose Unawareness State Minimally Conscious State Vegetative State Disorder of Consciousness Post-Traumatic Coma Neurological Injury Traumatic Brain Injury Diagnosis Cognitive Dysfunction Neurological Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Completed 18 years of age.
2. Consent of the legal guardian to participate in the Study and access to medical records.
3. Medical diagnosis indicating damage to the central nervous system.
4. Having and sharing a description of imaging tests (alternatively MRI - Magnetic Resonance Imaging or CT - Computed Tomography) and (alternatively) ophthalmoscopy, ophthalmology, auditory tests.
5. Presentation of a list of medications used by the patient that may affect the results obtained in tests of cognitive function.
6. Acceptance by a physician (e.g. neurologist, neurosurgeon, internist) to participate in a clinical trial, taken after reviewing the Study protocol, including there is a need to take into account:

1. the ability to communicate only by sight (no verbal, sign or other communication),
2. the absence of dementia and aphasic disorders before the event that led to CNS damage and the patient's current condition,
3. preserved at least one functioning eyeball (possibility of cooperation with an eye tracker).

Exclusion Criteria

1. Visual defect (refractive defect) diagnosed before the incident, requiring work with glasses with lenses of more than ±3 diopters.
2. Inclusion of drug treatment during the Study (observation), which can affect the patient's cognitive functioning (both in terms of cognitive enhancement and impairment/dementia).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No